SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets earnings miss, slower Search and advertising growth, and heavy AI spending that pushed free cash flow negative drove the sharp selloff, despite strong Google Cloud growth. Traders are split between calling the drop an overreaction and buying the dip, and worrying that AI could pressure Search monetization and that the investment may not generate adequate returns.

Alphabet Inc - Ordinary Shares - Class C

Alphabets quarterly earnings miss and heavy AI infrastructure spending, which pressured cash flow, triggered a sharp selloff. Traders are split between concerns that AI competition is weakening Search monetization and doubts about returns on spending, and bullish arguments that rapid Cloud growth makes the drop an overreaction.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly results beat expectations as Azure growth accelerated, prompting an initial positive reaction. Traders are divided after the stock gave back much of that move, weighing strong cloud demand and cash generation against heavy AI infrastructure spending, capacity delays, and broader weakness following Alphabets results.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed quarterly results and softer outlook for near-term contracted revenue growth sparked a sharp selloff, with investors debating whether AI demand can offset slowing growth and high expectations. Many traders call the reaction an overreaction given the companys revenue growth and raised AI targets, while others see the outlook as a reason to reassess its valuation and software-sector risks.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated lifileucel data in non-small-cell lung cancer sparked a sharp selloff, despite response rates holding near prior results and stronger signals in a biomarker-selected subgroup. Traders are split between viewing the subgroup findings as a promising precision-treatment opportunity and worrying that a narrower eligible population, further validation, and regulatory timing could limit or delay the commercial upside.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons upcoming quarterly report is the dominant focus, with traders watching AWS growth and whether AI spending can translate into stronger margins and cash flow. Some expect strong cloud results and a favorable reaction, while others fear that heavy capex and the selloff after Alphabets report could weigh on the shares even if Amazon beats expectations.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports that Marvell is in advanced talks to acquire Lumentum have focused attention on LITE, though no deal is final. Traders are divided between seeing strategic value in Lumentums scarce AI-data-center optics and questioning the rumor, potential financing and dilution, as the shares swing sharply.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines quarterly earnings beat and raised full-year outlook are driving the rally, with traders welcoming signs of improved performance after a prolonged downturn. The community is broadly bullish and speculates that heavy short interest could amplify gains, while others point to debt, weaker yields, fuel costs and profit-taking as risks.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles long-term growth outlook and plan to reach positive free cash flow while limiting additional financing eased AI-spending and debt concerns, prompting a sharp rally. Traders remain divided over whether the projections are credible and executable, while some attribute the subsequent pullback to profit-taking and spillover from Alphabets results.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings Q3 update and the CEOs estimate that VK2735 may not reach commercialization for roughly two and a half years have fueled concern about the long wait, cash burn and potential dilution. Traders are divided over partnering or selling versus going it alone, while bulls cite Phase 3 progress and strong demand for obesity drugs as reasons for optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close...

Are Medical Stocks Lagging  Agilon Health (AGL) This Year?

Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensiveread more...

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Equity

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure

Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly.

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery Platform

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and...

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The...

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st...

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">NVAX</a> surged 20%, EBS gained 14%, ARCT rose 13% and MRNA climbed 7% amid the Russian plague scare.</li><li>The rally broadened to protective-equipment, antiviral and immune-profiling stocks, with LAKE gaining 15% and APT and NNVC each rising 13%.</li><li>Russian authorities called the regional situation stable, while the WHO assessed the public risk as low.</li></ul>A Russian lab worker’s unexplained death&nbsp;in a plague research institute sparked a rally across vaccine and biodefense stocks on Monday, with Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advancing as retail investors speculated about federal contracts and further gains.NVAX surged 20%,&nbsp;<a href="https://stocktwits.com/symbol/EBS">EBS</a> climbed 14%,&nbsp;<a href="https://stocktwits.com/symbol/ARCT">ARCT</a> gained 13% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA</a> rose 7%. Buying spread to protective-equipment suppliers, testing companies and antiviral developers as traders revived familiar outbreak bets.<img src="https://news.stocktwits-cdn.com/outbreak_rally_9d23a20745.png" alt="outbreak rally.png">The rally also extended to protective-equipment makers&nbsp;<a href="https://stocktwits.com/symbol/APT">Alpha Pro Tech (APT)</a>, which rose 13% on Monday, and&nbsp;<a href="https://stocktwits.com/symbol/LAKE">Lakeland Industries (LAKE)</a>, which gained 15%. Antiviral developer&nbsp;<a href="https://stocktwits.com/symbol/NNVC">NanoViricides (NNVC)</a> climbed 13%, immune-profiling company&nbsp;<a href="https://stocktwits.com/symbol/VRAX">Virax Biolabs (VRAX)</a> advanced 10%, and smallpox-drug maker&nbsp;<a href="https://stocktwits.com/symbol/SIGA">Siga Technologies (SIGA)</a> added 3%.&nbsp;Cancer-immunotherapy developer&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio (IBRX)</a>, which also featured in retail discussions about government demand, edged up 1%.&nbsp;&nbsp;<h2 class="st-heading-2">Trump’s Russia Offer Fuels Spending Hopes</h2>“We’ll help,” Trump said on Monday, calling the situation a “big problem for Russia,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-says-us-will-help-russia-after-siberia-plague-institute-death-2026-10-05/">reported</a>. The remarks came after the death of Darya Shipilova, a 28-year-old lab technician at the Irkutsk Anti-Plague Research Institute in Siberia. She developed pneumonia of unknown origin, prompting quarantine measures and medical observation of people who had contact with her.Russia’s public health agency, Rospotrebnadzor, said samples contained no microorganisms associated with her professional duties and called the regional epidemiological situation stable.&nbsp;The WHO said that the risk to the general population appeared low based on available unofficial information. U.S. Secretary of State Marco Rubio also urged measured attention, calling the situation a “cause for focus,” according&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2026/10/05/world/video/rubio-says-situation-in-russia-is-cause-for-focus-but-not-alarm">to</a> CNN.The uncertainty nevertheless gave traders a familiar catalyst: the prospect that heightened preparedness could lead to government purchases.<h2 class="st-heading-2">Vaccine Makers Ride Outbreak Bets</h2>Novavax, Moderna and Arcturus have commercial vaccines, but their products do not target plague. Novavax developed Nuvaxovid, a protein-based COVID-19 vaccine containing its Matrix-M adjuvant. Matrix-M enhances immune responses and can be incorporated into other vaccines, giving the company broader vaccine-development and licensing exposure.Moderna markets COVID-19 vaccines, including Spikevax, and the RSV vaccine mRESVIA. Its mRNA tech makes it a familiar name in emerging-pathogen trades.&nbsp;Meanwhile, Arcturus has the commercial COVID-19 vaccine Kostaive and is developing ARCT-2304, an experimental H5N1 pandemic-influenza vaccine. BARDA fully funds the candidate’s Phase 1 study.<h2 class="st-heading-2">Stockpile Suppliers And PPE Makers Rally</h2>Emergent has a direct connection to government purchasing through its medical-countermeasure portfolio. BioThrax and Cyfendus are anthrax vaccines, while ACAM2000 is a smallpox and mpox vaccine. Tembexa, another portfolio product, is a smallpox antiviral. Its $24 million BARDA contract modification for Cyfendus, announced last month, shows its procurement model.&nbsp;Siga supplies TPOXX, a smallpox antiviral, to the Strategic National Stockpile. Lakeland and Alpha Pro Tech provide protective equipment. Lakeland supplies protective clothing, while Alpha Pro Tech manufactures disposable garments, masks and face shields.&nbsp;<h2 class="st-heading-2">Antiviral And Immunotherapy Names Join Rally</h2>Virax Biolabs focuses on immune-response detection and T-cell profiling, including applications in post-acute infection syndromes such as Long COVID. NanoViricides is developing NV-387, an antiviral drug candidate. Because plague is bacterial, its rally reflects broader outbreak sentiment rather than an established plague-treatment opportunity.Meanwhile, ImmunityBio markets Anktiva, a cancer immunotherapy, and develops immune-cell platforms.<h2 class="st-heading-2">How Do Retail Traders Feel About Outbreak Bets?</h2>On Stocktwits, retail sentiment for NVAX and EBS was ‘extremely bullish’ amid ‘extremely high’ message volume. ARCT drew ‘bullish’ sentiment with ‘normal’ chatter, while MRNA sentiment remained ‘neutral’ despite ‘high’ message volume.&nbsp;One user on EBS&nbsp;<a href="https://stocktwits.com/KnuckleSandwich/message/665783238">said</a>: “Contract awards are in bound....good timing with the Russia plague news fueling the momentum!!” The user added: “See you at 15++.. Might even hit 20 by year-end!” Another user on NVAX&nbsp;<a href="https://stocktwits.com/TobySmith1366/message/665803930">sees</a> a return to “operation warp speed” and “throwing billions at NVAX.”One user on APT&nbsp;<a href="https://stocktwits.com/Paretoprincipal/message/665752847">drew parallels</a> with a previous outbreak trade: “Hantavirus took APT from $4.50 to $7.50 this May. The plague should take us even higher.” Another user on NNVC&nbsp;<a href="https://stocktwits.com/insanitywolftrading/message/665786543">noted</a> that “every time there is a pandemic fear this makes a massive run.”So far this year, NVAX has gained 87%, MRNA has surged 589% and ARCT has climbed 139%, while EBS remains down 41%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-trillionaire-sequoia-maguire-investors-starting-to-understand-spacex/cZDsnwARBjv">SPCX Stock Makes Musk A Trillionaire Again: Sequoia's Maguire Says Investors Are Just 'Starting To Understand SpaceX'&nbsp;</a>

Alpha Pro Tech Ltd.

Emergent Biosolutions Inc

ImmunityBio Inc

Lakeland Industries, Inc.

Moderna Inc

NanoViricides Inc

Novavax Inc

SIGA Technologies Inc

Virax Biolabs Group Ltd

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$12.16
Prev Close	$12.07
Open	$12.22
Dividend Yield	0.00%
50-Day Moving Average	$13.57
Beta	1.79
Avg. Volume	898,427.40
PE Ratio	-3.64

52-Week High	$17.96
52-Week Low	$5.50
Market Capitalization	$343.07M
EPS (Annual)	-$2.40
Price to Book	2.00
Revenue Per Employee	$605,594.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARCT Fundamentals